Prognostic value of subclinical thyroid dysfunction in ischemic stroke patients treated with intravenous thrombolysis

Aging (Albany NY). 2019 Sep 3;11(17):6839-6850. doi: 10.18632/aging.102215. Epub 2019 Sep 3.

Abstract

Data regarding the association between subclinical thyroid dysfunction and clinical outcomes in ischemic stroke patients with intravenous thrombolysis (IVT) are limited. We aimed to investigate the predictive value of subclinical thyroid dysfunction in END, functional outcome and mortality at 3 months among IVT patients. We prospectively recruited 563 IVT patients from 5 stroke centers in China. Thyroid function status was classified as subclinical hypothyroidism, subclinical hyperthyroidism (SHyper) and euthyroidism. The primary outcome was END, defined as ≥ 4 point in the NIHSS score within 24 h after IVT. Secondary outcomes included 3-month functional outcome and mortality. Of the 563 participants, END occurred in 14.7%, poor outcome in 50.8%, and mortality in 9.4%. SHyper was an independent predictor of END [odd ratio (OR), 4.35; 95% confidence interval [CI], 1.86-9.68, P = 0.003], 3-month poor outcome (OR, 3.24; 95% CI, 1.43-7.33, P = 0.005) and mortality [hazard ratio, 2.78; 95% CI, 1.55-5.36, P = 0.003]. Subgroup analysis showed that there was no significant relationship between SHyper and clinical outcomes in IVT patients with endovascular therapy. In summary, SHyper is associated with increased risk of END, and poor outcome and mortality at 3 months in IVT patients without endovascular therapy.

Keywords: early neurological deterioration; ischemic stroke; subclinical hyperthyroidism; subclinical hypothyroidism; thrombolysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cohort Studies
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Stroke / complications*
  • Stroke / drug therapy*
  • Thrombolytic Therapy / methods
  • Thyroid Diseases / complications*
  • Thyroid Diseases / epidemiology
  • Treatment Outcome

Substances

  • Fibrinolytic Agents